Note the stated benefit does not make adjustments for the half dozen+ pro-drug flaws*, and biases* in the short term corporate studies.
In meta-analyses of corporate short term studies (the most pro-drug biased* studies available) the benefit of drugs marketed as antidepressants is "mean improvement was 9.60 points on the HRSD in the drug groups and 7.80 in the placebo groups, yielding a mean drug–placebo difference of 1.80 on HRSD improvement scores"(1). In the HRSD ...